CHFR and cancer: The mitotic checkpoint gene “checkpoint with forkhead and ringfinger domains” (CHFR) has recently emerged as a critical mediator of resistance against microtubular-targeted therapies in various different cancer types including gastric-[1], colon-[2, 3], endometrial-,[4, 5] and lung cancer [6].